DDS vs TSLA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
DDS exhibits exceptional financial health with a Piotroski F-Score of 8/9 and a very low Debt/Equity ratio of 0.31. However, the stock is significantly overvalued, trading at $595.20—nearly double its Graham Number ($305.57) and Intrinsic Value ($255.01). While profitability remains high with an ROE of 31.90%, the company is facing a growth stagnation with negative YoY revenue and earnings growth. The disconnect between strong fundamental health and poor valuation/growth metrics suggests a limited upside from current levels.
Tesla's deterministic health is marginally stable with a Piotroski F-Score of 4/9, but the valuation is fundamentally decoupled from financial performance. The stock trades at a massive premium to its Graham Number ($23.07) and Intrinsic Value ($7.56), while exhibiting negative revenue growth (-3.10%) and a severe collapse in earnings growth (-60.60%). With zero earnings beats in the last four quarters and bearish insider activity, the current price is supported by sentiment rather than data.
Compare Another Pair
Related Comparisons
DDS vs TSLA: Head-to-Head Comparison
This page compares Dillard's, Inc. (DDS) and Tesla, Inc. (TSLA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.